Management of Graves' Hyperthyroidism: More Than a Century of Progression

被引:2
|
作者
Abdi, Hengameh [1 ]
Amouzegar, Atieh [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Endocrine Res Ctr, Res Inst Endocrine Sci, Tehran, Iran
关键词
Hyperthyroidism; Surgery; Graves' Disease; Radioiodine; Antithyroid Drug; AMERICAN THYROID ASSOCIATION; ANTITHYROID DRUG-THERAPY; RADIOIODINE TREATMENT; CANCER-MORTALITY; I-131; THERAPY; FOLLOW-UP; DISEASE; OPHTHALMOPATHY; GUIDELINES; DIAGNOSIS;
D O I
10.5812/ijem.103943
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: There are three therapeutic modalities for the management of Graves' disease (GD), including thyroid surgery, radioactive iodine (RAI), and antithyroid drugs (ATDs). We aimed to briefly review the history of these treatment strategies and their advantages and disadvantages. Evidence Acquisition: We searched PubMed for English language articles using pertinent search terms. Results: Each treatment modality for GD is accompanied by several advantages and disadvantages. Nowadays, ATDs are the most commonly prescribed therapy for GD worldwide. The lack of well-designed, large RCTs comparing three different treatments for hyperthyroidism concerning various short-term and long-term outcomes has led to remarkable uncertainty in the preference of each of these treatments, as is evident in relevant guidelines from different societies. Recently, the efficacy and safety of long-term use of ATDs have been documented. Conclusions: Pros and cons of each therapeutic modality for Graves' hyperthyroidism should be taken into account during the physician-patient discussion to select the primary treatment. Considering recent data about the long-term efficacy and safety of ATDs, it seems that the appropriate selection of Graves' patients for long-term ATD therapy can be a new avenue in the treatment and even cure of GD.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Current controversies in the management of Graves' hyperthyroidism
    Francis, Niroshan
    Francis, Thanuya
    Lazarus, John H.
    Okosieme, Onyebuchi E.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2020, 15 (03) : 159 - 169
  • [2] Management of Graves' hyperthyroidism: present and future
    Bartalena, Luigi
    Piantanida, Eliana
    Gallo, Daniela
    Ippolito, Silvia
    Tanda, Maria Laura
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2022, 17 (02) : 153 - 166
  • [3] The Long-Term Outcome of Treatment for Graves' Hyperthyroidism
    Sjolin, Gabriel
    Holmberg, Mats
    Torring, Ove
    Bystroem, Kristina
    Khamisi, Selwan
    de Laval, Dorota
    Abraham-Nordling, Mirna
    Calissendorff, Jan
    Lantz, Mikael
    Hallengren, Bengt
    Filipsson Nystrom, Helena
    Wallin, Goran
    THYROID, 2019, 29 (11) : 1545 - 1557
  • [4] Effect of Different 131I Dose Strategies for Treatment of Hyperthyroidism on Graves' Ophthalmopathy
    Ariamanesh, Shahrara
    Ayati, Narjess
    Mazloum Khorasani, Zahra
    Mousavi, Zohreh
    Kiavash, Victoria
    Kiamanesh, Zahra
    Zakavi, Seyed Rasoul
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (07) : 514 - 518
  • [6] Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves' Orbitopathy: A Retrospective Cohort Study
    Cosentino, Giada
    Lanzolla, Giulia
    Comi, Simone
    Maglionico, Maria Novella
    Posarelli, Chiara
    Ciampa, Dali Antonia
    Menconi, Francesca
    Rocchi, Roberto
    Latrofa, Francesco
    Figus, Michele
    Santini, Ferruccio
    Marino, Michele
    THYROID, 2025, : 298 - 306
  • [7] Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any)
    Bartalena, L.
    Chiovato, L.
    Vitti, P.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2016, 39 (10) : 1105 - 1114
  • [8] Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye
    Sabini, Elena
    Ionni, Ilaria
    Rocchi, Roberto
    Vitti, Paolo
    Marcocci, Claudio
    Marino, Michele
    EUROPEAN THYROID JOURNAL, 2018, 7 (01) : 51 - 54
  • [9] Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism
    Wiersinga, Wilmar
    Zarkovic, Milos
    Bartalena, Luigi
    Donati, Simone
    Perros, Petros
    Okosieme, Onyebuchi
    Morris, Daniel
    Fichter, Nicole
    Lareida, Jurg
    von Arx, Georg
    Daumerie, Chantal
    Burlacu, Maria-Christina
    Kahaly, George
    Pitz, Susanne
    Beleslin, Biljana
    Ciric, Jasmina
    Ayvaz, Goksun
    Konuk, Onur
    Toruner, Fusun Balos
    Salvi, Mario
    Covelli, Danila
    Curro, Nicola
    Hegedus, Laszlo
    Brix, Thomas
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2018, 178 (06) : 635 - 643
  • [10] A patient-specific treatment model for Graves' hyperthyroidism
    Pandiyan, Balamurugan
    Merrill, Stephen J.
    Di Bari, Flavia
    Antonelli, Alessandro
    Benvenga, Salvatore
    THEORETICAL BIOLOGY AND MEDICAL MODELLING, 2018, 15